Zepbound outduels Wegovy in weight-loss clinical trial
May 14, 2025
May 14, 2025
ITHACA, New York, May 14 -- Cornell University posted the following news:
* * *
Zepbound outduels Wegovy in weight-loss clinical trial
Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical trial that compared the safety and efficacy of the injectable drugs.
In the 72-week trial - led by an investigator at Weill Cornell Medicine and NewYork-Presbyterian . . .
* * *
Zepbound outduels Wegovy in weight-loss clinical trial
Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical trial that compared the safety and efficacy of the injectable drugs.
In the 72-week trial - led by an investigator at Weill Cornell Medicine and NewYork-Presbyterian . . .